CompletedPhase 2NCT04731103
Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome
Studying Aicardi-Goutières syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Edinburgh
- Principal Investigator
- Yanick CrowUniversity of Edinburgh
- Intervention
- Abacavir (ABC)(drug)
- Enrollment
- 13 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2022 – 2024
Study locations (1)
- Yanick Crow, Edinburgh, United Kingdom
Collaborators
NHS Lothian · Medical Research Council
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04731103 on ClinicalTrials.gov